Filing identity and reporting period
Important mismatch: The supplied filing is Bionomics Limited’s Form 20-F, not a filing for Neuphoria Therapeutics Inc. It is an annual report for the fiscal year ended June 30, 2023, not a 2022 Q4 report. Financial statements are prepared under IFRS in Australian dollars (A$).
Bionomics is a clinical-stage biopharmaceutical company developing CNS therapies. Its lead candidate, BNC210, is being developed for PTSD and social anxiety disorder (SAD). The company reported no approved products and no product sales revenue.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | A$22,000 | A$264,000 |
| Other income, principally R&D incentives | A$628,000 | A$5.80 million |
| Research and development expense | A$19.61 million | A$16.00 million |
| Loss before tax | A$32.05 million | A$21.95 million |
| Net loss | A$31.85 million | A$21.76 million |
| Basic and diluted loss per share | A$0.02 | A$0.02 |
| Cash used in operating activities | A$21.34 million | A$21.76 million |
| Cash and cash equivalents at year-end | A$18.25 million | A$33.56 million |
- FY2023 total assets were A$43.00 million, total liabilities A$9.86 million, and net assets A$33.15 million, down from A$65.31 million, A$8.40 million, and A$56.91 million, respectively, in FY2022.
- Current assets were A$20.10 million against current liabilities of A$4.13 million. The company had A$0.53 million of lease liabilities and reported no bank borrowings at year-end.
- Financing activities generated A$5.56 million in FY2023, largely from share issuance; cash declined A$15.31 million overall. There were no dividends.
- The filing says cash, together with anticipated financing transactions, was expected to fund development activities through October 31, 2024. This estimate depends on assumptions and additional financing is not assured.
Changes from the prior comparable year
- Net loss widened by approximately A$10.09 million, while R&D expense rose 23% to A$19.61 million, mainly reflecting the ATTUNE PTSD and PREVAIL SAD trials and SAD regulatory planning.
- Other income fell A$5.17 million, primarily because recognized Australian R&D incentives declined from A$5.80 million to A$0.63 million. The cash flow statement separately records A$6.72 million of R&D incentive receipts in FY2023, reflecting timing differences.
- Cash fell A$15.31 million, and net assets declined A$23.76 million. Administration expense rose 17% to A$8.64 million, partly due to the new CEO and U.S.-based consultants.
- The fair-value liability for contingent consideration increased to A$3.69 million, generating a FY2023 expense of A$0.99 million.
Outlook, development updates, and key risks
- PTSD: After year-end, Bionomics announced that the Phase 2b ATTUNE trial met its primary endpoint at Week 12 (p=0.048), with significant results also reported at Weeks 4 and 8. The 12-week study enrolled 212 patients and tested 900 mg twice daily. Management planned to start Phase 3 in the second half of 2024, contingent on raising capital.
- SAD: The Phase 2 PREVAIL trial did not meet its prespecified primary endpoint. The company reported favorable trends in post-hoc analyses; these do not replace the failed primary analysis or establish confirmatory efficacy. Following an FDA end-of-Phase-2 meeting, management planned a Phase 3 study, with dosing targeted for the quarter ending March 31, 2024, subject to financing.
- BNC210 has Fast Track designation for PTSD and SAD. The filing reports commonly observed adverse events including headache, somnolence, and nausea, and notes reports of elevated liver function tests in ATTUNE participants receiving 900 mg twice daily.
- The company had an at-the-market (ATM) program permitting up to US$11.5 million in sales. By September 30, 2023, it had sold 2,100,866 ADSs for US$6.72 million gross and US$6.41 million net proceeds. Further equity funding may dilute shareholders; the planned clinical program depends on securing capital.
- MSD funds and controls development of partnered alpha-7 PAM candidates; potential milestones and royalties depend on MSD’s decisions and program success. Carina Biotech’s BNC101 program could generate milestone and royalty payments, but no payments had been received under that agreement as of the filing.
- Key risks include clinical and regulatory failure or delay, reliance on third-party manufacturers and trial operators, limited cash and financing access, competition, intellectual-property challenges, and currency exposure. The ASX delisting became effective August 28, 2023, leaving Nasdaq ADSs as the public listing.
- Ernst & Young issued an unqualified opinion on the IFRS financial statements. The filing did not include management’s internal-control assessment or an auditor attestation, citing transition relief for a newly public company and emerging growth company status.
Investor verification priorities
- Confirm the issuer and period: this is Bionomics Limited’s FY2023 annual report, not a Neuphoria filing or a 2022 Q4 filing.
- Review audited financial statements and cash forecasts, especially the October 31, 2024 runway estimate and assumptions about future financing.
- Examine full ATTUNE results, including effect size and safety data, and distinguish the post-hoc PREVAIL findings from its failed primary endpoint.
- Track ATM proceeds, ADS issuance, remaining capacity, and resulting dilution after September 30, 2023.
- Check subsequent regulatory, trial, financing, and collaboration disclosures, including elevated liver-function findings and the status of planned Phase 3 studies.